1. Home
  2. KIDS vs CBIO Comparison

KIDS vs CBIO Comparison

Compare KIDS & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OrthoPediatrics Corp.

KIDS

OrthoPediatrics Corp.

HOLD

Current Price

$22.72

Market Cap

588.8M

Sector

Health Care

ML Signal

HOLD

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$14.67

Market Cap

537.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KIDS
CBIO
Founded
2007
2003
Country
United States
United States
Employees
602
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
588.8M
537.5M
IPO Year
2016
2013

Fundamental Metrics

Financial Performance
Metric
KIDS
CBIO
Price
$22.72
$14.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
6
Target Price
$24.67
★ $26.67
AVG Volume (30 Days)
151.7K
★ 390.5K
Earning Date
04-30-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $98,049,000.00
$18,500.00
Revenue This Year
$14.07
N/A
Revenue Next Year
$11.85
$279.20
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 37.95
N/A
52 Week Low
$14.42
$8.72
52 Week High
$26.74
$27.41

Technical Indicators

Market Signals
Indicator
KIDS
CBIO
Relative Strength Index (RSI) 49.17 35.19
Support Level $21.00 $9.95
Resistance Level $23.51 $18.53
Average True Range (ATR) 0.78 1.45
MACD 0.00 -0.52
Stochastic Oscillator 61.75 13.36

Price Performance

Historical Comparison
KIDS
CBIO

About KIDS OrthoPediatrics Corp.

OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: